New medication treats drug-resistant prostate cancer in the laboratory
- Posted: June 18, 2013
A new drug called pyrvinium pamoate inhibits aggressive forms of prostate cancer that are resistant to standard drugs, according to a study conducted in an animal model by the City of Hope, Beckman Research Institute, in Duarte, Calif. The results were presented at The Endocrine Society's 95th Annual Meeting in San Francisco.
Among the research institutions NCI funds across the United States, it currently designates 67 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.